Allergan makes sizable donation to liver disease research

Allergan has made a substantial donation to the American Association for the Study of Liver Diseases (AASLD) Foundation, becoming part of AASLD’s Founder’s Society.
“AASLD Foundation is proud of the impact we are making,” Bruce Bacon, AASLD board of trustee chair, said in a press release. “In 2016 we invested $2.63 million to fund ideas of bright young investigators and to provide training opportunities for future hepatology leaders. However, we know there is so much more to be done, and we are grateful that Allergan recognizes that, too.”
AASLD is the largest private supporter of hepatology research in the U.S.
“Allergan is focused on identifying, developing and bringing forward innovative treatments for patients with significant unmet medical needs, including non-alcoholic steatohepatitis,” Gavin Corcoran, chief medical officer at Allergan, said. “This donation underscores Allergan’s commitment to supporting research and educational initiatives that advance medical innovation and the ability to save more lives, which is possible through increased research and enhanced hepatology training opportunities.”